Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2017 | Review

Deptor: not only a mTOR inhibitor

Authors: Valeria Catena, Maurizio Fanciulli

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Abstract

Deptor is an important protein that belongs to the mTORC1 and mTORC2 complexes, able to interact with mTOR and to inhibit its kinase activity. As a natural mTOR inhibitor, Deptor is involved in several molecular pathways, such as cell growth, apoptosis, autophagy and ER stress response. For this reason, Deptor seems to play an important role in controlling cellular homeostasis. Despite several recent insights characterizing Deptor functions and regulation, its complete role within cells has not yet been completely clarified. Indeed, quite recently, Deptor has been associated with chromatin, and it has been demonstrated having a role in transcriptional regulation, controlling in such way endoplasmatic reticulum activity.

From all these observations it is not surprising that Deptor can behave either as an oncogene or oncosuppressor, depending on the cell- or tissue-contexts. This review highlights recent progresses made in our understanding of the many activities of Deptor, describing its transcriptional and post-transcriptional regulation in different cancer cell types. Moreover, here we discuss the possibility of using compounds able to inhibit Deptor or to disrupt its interaction with mTOR as novel approaches for cancer therapy.

Wang Z, Zhong J, Inuzuka H, Gao D, Shaik S, Sarkar FH, et al. An evolving role for DEPTOR in tumor development and progression. Neoplasia. 2012;14(5):368–75.CrossRefPubMedPubMedCentral

Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137(5):873–86. doi:10.1016/j.cell.2009.03.046.CrossRefPubMedPubMedCentral

Panic N, Larghi A, Amore R, Pastorino R, Bulajic M, Costamagna G, et al. Single nucleotide polymorphisms within the 8Q24 region are not associated with the risk of intraductal papillary mucinous neoplasms of the pancreas. J Gastrointestin Liver Dis. 2016;25(3):311–5. doi:10.15403/jgld.2014.1121.253.q24.PubMed

Chen S, Hamm HE. DEP domains: more than just membrane anchors. Dev Cell. 2006;11(4):436–8. doi:10.1016/j.devcel.2006.09.011.CrossRefPubMed

Zhao Y, Xiong X, Sun Y. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell. 2011;44(2):304–16. doi:10.1016/j.molcel.2011.08.029.CrossRefPubMedPubMedCentral

Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004;36(1):40–5. doi:10.1038/ng1285.CrossRefPubMed

Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A. 2004;101(16):6062–7. doi:10.1073/pnas.0400782101.CrossRefPubMedPubMedCentral

Catena V, Bruno T, De Nicola F, Goeman F, Pallocca M, Iezzi S, et al. Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells. Oncotarget. 2016. doi:10.18632/oncotarget.12060.PubMed

Liu NB, Zhang JH, Liu YF, Li J, Zhang ZZ, Li JW, et al. High DEPTOR expression correlates with poor prognosis in patients with esophageal squamous cell carcinoma. OncoTargets Ther. 2015;8:3449–55. doi:10.2147/OTT.S92862.

10.

Li H, Sun GY, Zhao Y, Thomas D, Greenson JK, Zalupski MM, et al. DEPTOR has growth suppression activity against pancreatic cancer cells. Oncotarget. 2014;5(24):12811–9. doi:10.18632/oncotarget.2659.CrossRefPubMedPubMedCentral

11.

Zhou X, Guo J, Ji Y, Pan G, Liu T, Zhu H, et al. Reciprocal negative regulation between EGFR and DEPTOR plays an important role in the progression of lung adenocarcinoma. Mol Cancer Res. 2016;14(5):448–57. doi:10.1158/1541-7786.MCR-15-0480.CrossRefPubMed

12.

Laplante M, Sabatini DM. mTOR Signaling. Cold Spring Harb Perspect Biol. 2012;4(2). doi:10.1101/cshperspect.a011593.

13.

Kim LC, Cook RS, Chen J. mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene. 2016. doi:10.1038/onc.2016.363.

14.

Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–93. doi:10.1016/j.cell.2012.03.017.CrossRefPubMedPubMedCentral

15.

Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21–35. doi:10.1038/nrm3025.CrossRefPubMed

16.

Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501. doi:10.1038/nrc839.CrossRefPubMed

17.

Zhang H, Chen J, Zeng Z, Que W, Zhou L. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro. Int J Mol Med. 2013;31(5):1127–34. doi:10.3892/ijmm.2013.1299.PubMed

18.

Kazi AA, Hong-Brown L, Lang SM, Lang CH. Deptor knockdown enhances mTOR Activity and protein synthesis in myocytes and ameliorates disuse muscle atrophy. Mol Med. 2011;17(9–10):925–36. doi:10.2119/molmed.2011.00070.PubMedPubMedCentral

19.

Agrawal P, Reynolds J, Chew S, Lamba DA, Hughes RE. DEPTOR is a stemness factor that regulates pluripotency of embryonic stem cells. J Biol Chem. 2014;289(46):31818–26. doi:10.1074/jbc.M114.565838.CrossRefPubMedPubMedCentral

20.

Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221(1):3–12. doi:10.1002/path.2697.CrossRefPubMedPubMedCentral

21.

Eskelinen EL. The dual role of autophagy in cancer. Curr Opin Pharmacol. 2011;11(4):294–300. doi:10.1016/j.coph.2011.03.009.CrossRefPubMed

22.

Gao D, Inuzuka H, Tan MK, Fukushima H, Locasale JW, Liu P, et al. mTOR drives its own activation via SCF(betaTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell. 2011;44(2):290–303. doi:10.1016/j.molcel.2011.08.030.CrossRefPubMedPubMedCentral

23.

Lee MN, Ha SH, Kim J, Koh A, Lee CS, Kim JH, et al. Glycolytic flux signals to mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of Rheb. Mol Cell Biol. 2009;29(14):3991–4001. doi:10.1128/MCB.00165-09.CrossRefPubMedPubMedCentral

24.

Antonioli M, Albiero F, Nazio F, Vescovo T, Perdomo AB, Corazzari M, et al. AMBRA1 interplay with cullin E3 ubiquitin ligases regulates autophagy dynamics. Dev Cell. 2014;31(6):734–46. doi:10.1016/j.devcel.2014.11.013.CrossRefPubMed

25.

Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, Iezzi S, et al. Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy. EMBO J. 2015;34(9):1214–30. doi:10.15252/embj.201489920.CrossRefPubMedPubMedCentral

26.

Yu L, McPhee CK, Zheng L, Mardones GA, Rong Y, Peng J, et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature. 2010;465(7300):942–6. doi:10.1038/nature09076.CrossRefPubMedPubMedCentral

27.

Davies J, Zachariades E, Rogers-Broadway KR, Karteris E. Elucidating the role of DEPTOR in Alzheimer’s disease. Int J Mol Med. 2014;34(5):1195–200. doi:10.3892/ijmm.2014.1895.PubMedPubMedCentral

28.

Bruneau S, Nakayama H, Woda CB, Flynn EA, Briscoe DM. DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. Blood. 2013;122(10):1833–42. doi:10.1182/blood-2013-03-488486.CrossRefPubMedPubMedCentral

29.

Meng ZX, Wang L, Xiao Y, Lin JD. The Baf60c/Deptor pathway links skeletal muscle inflammation to glucose homeostasis in obesity. Diabetes. 2014;63(5):1533–45. doi:10.2337/db13-1061.CrossRefPubMedPubMedCentral

30.

Obeng EA, Carlson LM, Gutman DM, Harrington Jr WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907–16. doi:10.1182/blood-2005-08-3531.CrossRefPubMedPubMedCentral

31.

Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10(11):2034–42. doi:10.1158/1535-7163.MCT-11-0433.CrossRefPubMed

32.

Duan S, Skaar JR, Kuchay S, Toschi A, Kanarek N, Ben-Neriah Y, et al. mTOR generates an auto-amplification loop by triggering the betaTrCP- and CK1alpha-dependent degradation of DEPTOR. Mol Cell. 2011;44(2):317–24. doi:10.1016/j.molcel.2011.09.005.CrossRefPubMedPubMedCentral

33.

Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem. 2009;78:399–434. doi:10.1146/annurev.biochem.78.101807.093809.CrossRefPubMed

34.

Yoon MS, Rosenberger CL, Wu C, Truong N, Sweedler JV, Chen J. Rapid mitogenic regulation of the mTORC1 inhibitor, DEPTOR, by phosphatidic acid. Mol Cell. 2015;58(3):549–56. doi:10.1016/j.molcel.2015.03.028.CrossRefPubMedPubMedCentral

35.

Iezzi S, Fanciulli M. Discovering Che-1/AATF: a new attractive target for cancer therapy. Front Genet. 2015;6:141. doi:10.3389/fgene.2015.00141.CrossRefPubMedPubMedCentral

36.

Bruno T, De Nicola F, Iezzi S, Lecis D, D’Angelo C, Di Padova M, et al. Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell. 2006;10(6):473–86. doi:10.1016/j.ccr.2006.10.012.CrossRefPubMed

37.

Hu Y, Su H, Liu C, Wang Z, Huang L, Wang Q, et al. DEPTOR is a direct NOTCH1 target that promotes cell proliferation and survival in T-cell leukemia. Oncogene. 2016. doi:10.1038/onc.2016.275.

38.

Obara A, Fujita Y, Abudukadier A, Fukushima T, Oguri Y, Ogura M, et al. DEPTOR-related mTOR suppression is involved in metformin’s anti-cancer action in human liver cancer cells. Biochem Biophys Res Commun. 2015;460(4):1047–52. doi:10.1016/j.bbrc.2015.03.148.CrossRefPubMed

39.

Lai EY, Chen ZG, Zhou X, Fan XR, Wang H, Lai PL, et al. DEPTOR expression negatively correlates with mTORC1 activity and tumor progression in colorectal cancer. Asian Pac J Cancer Prev. 2014;15(11):4589–94.CrossRefPubMed

40.

Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A. 2014;111(1):409–14. doi:10.1073/pnas.1314469111.CrossRefPubMed

41.

Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell. 2008;30(6):701–11. doi:10.1016/j.molcel.2008.04.027.CrossRefPubMed

42.

Proud CG. Dynamic balancing: DEPTOR tips the scales. J Mol Cell Biol. 2009;1(2):61–3. doi:10.1093/jmcb/mjp012.CrossRefPubMed

43.

Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol. 2010;22(2):169–76. doi:10.1016/j.ceb.2009.10.007.CrossRefPubMed

44.

Srinivas KP, Viji R, Dan VM, Sajitha IS, Prakash R, Rahul PV, et al. DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase. Oncotarget. 2016;7(17):24154–71. doi:10.18632/oncotarget.8131.PubMedPubMedCentral

45.

Pei L, Xie P, Zhou E, Yang Q, Luo Y, Tang Z. Overexpression of DEP domain containing mTOR-interacting protein correlates with poor prognosis in differentiated thyroid carcinoma. Mol Med Rep. 2011;4(5):817–23. doi:10.3892/mmr.2011.503.PubMed

46.

Parvani JG, Davuluri G, Wendt MK, Espinosa C, Tian M, Danielpour D, et al. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression. Neoplasia. 2015;17(3):317–28. doi:10.1016/j.neo.2015.02.003.CrossRefPubMedPubMedCentral

47.

Zhang HR, Chen JM, Zeng ZY, Que WZ. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity. J Int Med Res. 2013;41(3):584–95. doi:10.1177/0300060513480920.CrossRefPubMed

48.

Boyd KD, Walker BA, Wardell CP, Ross FM, Gregory WM, Davies FE, et al. High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk lymphoma. 2010;51(11):2126–9. doi:10.3109/10428194.2010.509893.CrossRefPubMed

49.

Shi Y, Daniels-Wells TR, Frost P, Lee J, Finn RS, Bardeleben C, et al. Cytotoxic properties of a DEPTOR-mTOR inhibitor in multiple myeloma cells. Cancer Res. 2016. doi:10.1158/0008-5472.CAN-16-1019.

50.

Yang Y, Bardeleben C, Frost P, Hoang B, Shi Y, Finn R, et al. DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells. Genes Cancer. 2014;5(11–12):407–19. doi:10.18632/genesandcancer.44.PubMedPubMedCentral

51.

Pisani F, Petrucci MT, Giannarelli D, Bongarzoni V, Montanaro M, De Stefano V, et al. IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy. J Exp Clin Cancer Res. 2012;31:17. doi:10.1186/1756-9966-31-17.CrossRefPubMedPubMedCentral

Title: Deptor: not only a mTOR inhibitor
Authors: Valeria Catena
Maurizio Fanciulli
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-016-0484-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

High expression of Bruton’s tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma

MiR-203a-3p suppresses cell proliferation and metastasis through inhibiting LASP1 in nasopharyngeal carcinoma

Kindlin-2 promotes hepatocellular carcinoma invasion and metastasis by increasing Wnt/β-catenin signaling

PDGFA/PDGFRα-regulated GOLM1 promotes human glioma progression through activation of AKT

Autophagy maintains the stemness of ovarian cancer stem cells by FOXA2.

Inhibition of EGR1 inhibits glioma proliferation by targeting CCND1 promoter

Keynote webinar | Spotlight on antibody–drug conjugates in cancer